---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-026611"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:03:48.126421+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# KemPharm Q3 net loss widens to $0.19/shr; cash $107.4M, runway into 2026

## Summary
- Net loss of $6.6M ($0.19/share) vs loss of $1.8M ($0.05) in Q3 2021; revenue $2.9M (+45% YoY).
- R&D expense $5.4M (up from $2.2M) on KP1077 and arimoclomol programs; G&A $4.0M (up from $1.9M).
- Cash and investments $107.4M as of Sep 30, 2022; based on current forecast, runway extends into 2026.
- Arimoclomol NDA resubmission for NPC expected as early as Q3 2023; ongoing FDA discussions.
- KP1077 Phase 2 trial in IH to initiate by year-end 2022; Phase 1 CV safety trial completed.

## SEC filing metadata
- accession: 0001437749-22-026611
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774922026611/0001437749-22-026611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774922026611/kmph20220904_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-026611
- JSON: https://secwatch.observer/filing/0001437749-22-026611.json
- Plain text: https://secwatch.observer/filing/0001437749-22-026611.txt

## Key facts
- Earnings Releases
  ZEVRA THERAPEUTICS, INC. reported the third quarter ended September 30, 2022 results: revenue $2.9 million, net income ($6.6) million, or ($0.19) per basic and diluted share.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $2.9 million
  - Net income: ($6.6) million, or ($0.19) per basic and diluted share
  - Result: reported results
  source text: strategy could provide further capital flexibility and extend the operating cash runway. Overview of Third Quarter 2022 Financial Results: Net revenue for Q3 2022 was $2.9 million, as compared to Q3 2021 net revenue of $2.0 million. The period-over-period increase was primarily attributed to revenue from the arimoclomol Early Access Program (EAP) in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774922026611/0001437749-22-026611-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.